Profile
Sector:
HealthcareIndustry:
Medical DevicesCountry:
United StatesIPO:
15 October 2021Website:
http://www.paragon28.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 16 Jul 2024 20:07:01 GMTDividend
Analysts recommendations
Institutional Ownership
FNA Latest News
The dynamic functionality of Paragon 28's (FNA) Grappler R3INFORCE System sets it apart from traditional static repair systems, offering a more physiological and anatomical reconstruction option.
Paragon 28, Inc. (FNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Paragon 28, Inc. (FNA) Q4 2023 Earnings Call Transcript
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the CG 2024 Musculoskeletal Conference on Monday, February 12, 2024, at 1:00 p.m. Pacific Time / 2:00 p.m. Mountain Time. A live webcast, as well as the archived recording, will be available on the investor relations section.
Paragon 28's (FNA) BEAST Cortical Fibers' advanced processing capability ensures the preservation of native bone morphogenic proteins and other growth factors crucial for bone formation.
Paragon 28's (FNA) JAWS Great White Staple System is claimed to have 400 times greater fatigue life compared to competitors under similar load conditions.
Paragon 28, Inc. (NYSE:FNA ) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Matthew Brinckman - Senior Vice President, Strategy and IR Albert DaCosta - Chairman and CEO Steve Deitsch - Chief Financial Officer Conference Call Participants Matthew O'Brien - Piper Sandler Craig Bijou - Bank of America Caitlin Cronin - Canaccord George Sellers - Stephens, Inc. Brandon Vazquez - William Blair Mike Matson - Needham Dave Turkaly - JMP Securities Operator Good afternoon. And welcome to Paragon 28's Third Quarter 2023 Earnings Conference Call.
Paragon 28, Inc. (FNA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Paragon 28, Inc. (NYSE:FNA ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Matt Brinckman - SVP, Strategy and IR Albert DaCosta - Chairman and CEO Stephen Deitsch - CFO Conference Call Participants Craig Bijou - Bank of America Mike Matson - Needham & Company Matthew O'Brien - Piper Sandler Neil Chatterji - B. Riley Dave Turkaly - JMP Securities Kyle Rose - Canaccord George Sellers - Stephens Inc. Operator Good afternoon, and welcome to Paragon 28's Second Quarter 2023 Earnings Conference Call.
Paragon 28, Inc. (FNA) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.13 per share a year ago.
What type of business is Paragon 28?
Paragon 28, Inc. designs, develops, distributes, and sells foot and ankle surgical systems in the United States and internationally. It offers plating systems, including gorilla plating systems, such as lisfranc, lapidus, lateral column, calcaneus slide, and naviculocuneiform (NC) fusion plating systems; baby gorilla plate-specific screws, navicular fracture plates, and 5th metatarsal hook plates; and silverback plating systems. The company also provides precision guide technology for various procedures consisting of fusion, a procedure to address bunion deformities that fuses two bones on the big toe; first tarsometatarsal arthrodesis; and metatarsal osteotomy for bunion correction, medial column beaming for charcot foot reconstruction, ankle fusion plating, and NC joint arthrodesis. In addition, it offers monster, mini monster, and joust beaming screw systems for use in bone reconstruction, osteotomy, arthrodesis, joint fusion, ligament fixation, fracture repair, and fracture fixation; and APEX 3D total ankle replacement systems; total talus spacers to replace the talus and bone in the ankle that connects the leg and foot. Further, the company provides bunion or hallux valgus correction systems, including nail systems phantom intramedullary nail systems for the treatment of severe hallux valgus; and various orthobiologics comprising bone wedges, grafts, demineralized bone matrices, bone void fillers, synthetic materials, amniotic products, and a biocompatible collagen matrix, as well as PRESERVE bone graft systems for homologous application. Additionally, it offers soft tissue fixation systems, titanium sprayed polyetheretherketone implants, nitinol staple systems, stabilization systems, and curved instruments. The company serves hospitals and ambulatory surgery centers through a network of sales representatives and stocking distributors. Paragon 28, Inc. was founded in 2010 and is headquartered in Englewood, Colorado.
What sector is Paragon 28 in?
Paragon 28 is in the Healthcare sector
What industry is Paragon 28 in?
Paragon 28 is in the Medical Devices industry
What country is Paragon 28 from?
Paragon 28 is headquartered in United States
When did Paragon 28 go public?
Paragon 28 initial public offering (IPO) was on 15 October 2021
What is Paragon 28 website?
https://www.paragon28.com
Is Paragon 28 in the S&P 500?
No, Paragon 28 is not included in the S&P 500 index
Is Paragon 28 in the NASDAQ 100?
No, Paragon 28 is not included in the NASDAQ 100 index
Is Paragon 28 in the Dow Jones?
No, Paragon 28 is not included in the Dow Jones index
When was Paragon 28 the previous earnings report?
No data
When does Paragon 28 earnings report?
The next expected earnings date for Paragon 28 is 02 August 2024